***In silico* and *In vitro* evaluation of the anti-inflammatory and antioxidant potential of *Cymbopogon citratus* from North-western Himalayas**

Deeksha Salaria¹, Rajan Rolta¹, Nitin Sharma², Kamal Dev¹, Anuradha Sourirajan^{1*}, Vikas Kumar^{1*}

¹ Faculty of Applied sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Bajhol, PO Sultanpur, Distt. Solan-173229 (HP), India

² Department of Biotechnology, Chandigarh Group of Colleges, Landran, Mohali, Punjab, India

Correspondance:

Dr. Vikas Kumar/Prof. Anuradha Sourirajan
Faculty of Applied sciences and Biotechnology,
Shoolini University of Biotechnology and Management Sciences,
Bajhol, PO Sultanpur, Distt. Solan-173229 (HP), India
E-mail: vikaskmr59@gmail.com/asourirajan@gmail.com

Abstract

Cymbopogon citratus which is an aromatic perennial herb belonging to family Gramineae is known for its application in food and healthcare industry. The present study attempts to evaluate the potential of essential oil from *Cymbopogon citratus* (CEO) as an anti-inflammatory and antioxidant agent. CEO showed significant DPPH radical scavenging activity (IC_{50} - 91.0 ± 9.25 μ g/ml), as compared to Ascorbic acid (IC_{50} - 33.38 ± 2.29 μ g/ml). CEO also exhibited significant *in-vitro* anti-inflammatory activity with IC_{50} - 397.11 ± 1.45 μ g/ml) as compared to diclofenac sodium (IC_{50} - 682.98 ± 7.47 μ g/ml). Chemical constituents of the oil was determined using Gas Chromatography/Mass Spectroscopy, showed that 8-methyl-3,7-Nonadien-2-one (E), α -Pinene, limonene, citral, limonene oxide and Epoxy- α -terpenyl acetate were the major constituents. The *in silico* molecular docking study showed phytocompounds of CEO (Caryophyllene oxide and β -caryophyllene) have considerable binding potential with 1HD2 and 5IKQ receptors. PASS prediction of these phytocompounds also confirmed strong anti-inflammatory activity of *C. citratus*. The ADMET analysis also showed that these phytocompounds are safer to replace the synthetic drugs with side effects. This work establishes the anti inflammatory potential of CEO as an alternative to existing therapeutic approach to treatment of inflammation and also natural source of antioxidant compounds.

Keywords: *Cymbopogon citratus*; Essential oil; Antioxidant; Anti-inflammatory; Molecular docking.

Introduction

Aromatic and medicinal plants form the backbone of healthcare system for curing various ailments in developing countries including India. Essential oils are regarded as volatile plant components responsible for its aromatic nature [1]. The composition of essential oil varies from plant to plant; but flowers and aerial parts showed comparatively higher amount due to large number of oil producing glands. Because of its strong and pungent aroma, these essential oils primarily serve as insect repellent, thereby protecting them for insects. Other applications of essential oil are as flavoring agent in food and drug industry, starting material for the synthesis of complex medicinal compounds, therapeutic agent for skin and upper respiratory diseases, lipophilic solubility enhancer, carrier of drugs, cosmetic and in fragrance industries, etc [2].

Cymbopogon citratus (Gramineae), popularly known as citronella grass or lemongrass is perennial aromatic herb. The pharmacological activities of *C. citratus* have outstanding record in the folk and Ayurvedic medicine [3], [4]. The leaves of lemongrass can be used in both health and food field, as it contains phenol compounds which acts as antioxidant. *C. citratus* has been used for medical purposes to treat pathogenesis neurological disorders. *C. citratus* is considered as an effective agent in the prevention of various neurological diseases associated with oxidative stress [5]. It is reported to possess antibacterial [6], antifungal [7], antiprotozoal, anti-carcinogenic, anti-inflammatory [8], antioxidant [9], cardioprotective [10], anti-tussive, antiseptic, and anti-rheumatic activities [11]. It has also been used to inhibit platelet aggregation [12], treat diabetes [13], dyslipidemia, gastrointestinal disturbances [7], anxiety, malaria [14], flu, fever, and pneumonia [15], as well as in aromatherapy. In addition to its therapeutic uses, *C. citratus* is also consumed as a tea, added to non-alcoholic beverages, preservative in beverages, baked foods and cuisines [16]. In cosmetics, essential oil of *C. citratus* is used as fragrance in the manufacture of perfumes, soaps, detergents, and creams.

The present work attempts to identify major bioactive molecules present in the essential oil of *Cymbopogon citratus* leaves (CEO) through GC-MS technique. *In vitro* experiments were performed to evaluate antioxidant and anti-inflammatory potential of CEO leaves; Compounds identified through GC-MS were subjected to *in silico* studies to understand the mechanism of antioxidant and anti-inflammatory action. The docking studies predicted that the constituent molecules of *C. citratus* possess more capability as inhibitors as compared to established drugs in the pharmaceutical industry.

MATERIALS AND METHOD

Chemicals

The chemicals such as 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,4,6-Tri(2-pyridyl)-s-triazine (TPTZ), 2,2'-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), were obtained from Sigma-Aldrich Co. LLC, Mumbai. Methanol was procured from Loba Chemie Pvt. Ltd., Mumbai. Sodium Diclofenac (100 mg, Ranbaxy Laboratories Mohali, India) and fresh egg albumin were acquired from local market of Solan.

Collection of *C. citratus* and Extraction of *C. citratus* essential oil (CEO)

C. citratus leaves were collected from Palampur, Himachal Pradesh, India (32.1109° N, 76.5363° E) in the month of October 2019. The collected leaves of *C. citratus* were thoroughly washed with distilled water to remove the dust particles. Extraction of CEO was carried out by hydro-distillation method using cleverger assembly [17]. Extraction yield of CEO was determined based on the weight of leaves and oil obtained. The collected CEO was stored at 4 °C for further analysis.

Gas Chromatography-Mass Spectrometry analysis of CEO

The analysis of essential oil was performed using GC/MS instrument (Thermo Trace 1300 GC coupled with Thermo TSQ 800 Triple Quadrupole MS) fitted with a TG 5MS capillary column (30 m × 0.25 mm, 0.25 µm film thickness). Injector temperature was 280 and 250°C, respectively. The column temperature was held at 45 °C for 8 min and then increased to 250 °C at a rate of 28 °C /min and held at 250 °C for 16 min. Helium was used as a carrier gas, at a flow rate of 1.0 ml/min and mass spectra were recorded in the scan mode. The ionization voltage was 70 eV. The split ratio was 1:20. The ion source temperature was 175 °C, Interface temperature was 250 °C and 280°C. The constituents of essential oil were identified based on their retention time (R_t) with respect to the reference. The scan range was 40-700 m/z. The identification of compounds was based on matching unknown peaks with MS-data bank (NIST 2.0 electronic Library).

In vitro antioxidant activity of CEO

To analyze the antioxidant potential of CEO, different method such as DPPH, FRAP and ABTS method was employed. Various concentrations of oils (5-80 µg/ml) were prepared for each antioxidant assay, while Ascorbic acid was used as standard antioxidant compound for

all assays. Antioxidant capacity was expressed in terms of IC₅₀ (Half maximal inhibitory concentration), lower the value of IC₅₀, higher the antioxidant capacity.

DPPH radical scavenging activity

DPPH radical scavenging activity of CEO was measured by the method described by Barros *et al.* [18] and Rolta *et al* [19]. The capability of scavenging DPPH radical was calculated using the following equation:

$$\% \text{ DPPH radical scavenging activity} = \{ A_{(\text{control})} - A_{(\text{sample})} \} / A_{(\text{control})} \times 100$$

where A_(control) - Absorbance of control and A_(sample) - absorbance of the test/standard.

FRAP activity

FRAP activity was calculated according to the method described by Benzie and Strain [20]. The antioxidant capacity of CEO and ascorbic acid was calculated from the linear calibration curve of FeSO₄ (10 to 80 µM) and expressed as µM FeSO₄ equivalents.

ABTS scavenging assay

ABTS scavenging activity of CEO was calculated according to the method described by Re *et al.* [21]. Percentage ABTS scavenging activity was calculated as-

$$\text{ABTS radical scavenging activity (\%)} = [(A_{\text{control}} - A_{\text{sample}}) / (A_{\text{control}})] \times 100$$

Where, A_{control} is the absorbance of ABTS radical + methanol; A_{sample} is the absorbance of ABTS radical + sample /standard.

***In vitro* anti-inflammatory activity of CEO**

CEO was investigated for its inflammatory activity using denaturation of egg albumin method as per the reported method of Chandra *et al.* [22]; Gogoi *et al.* [23]. In this method, 200 µl of egg albumin (from fresh hen's egg), 2.8 ml of phosphate buffered saline (PBS, pH 6.4) and 2 ml of varying concentrations of the essential oil of *C. citratus* (50-400 µg/ml) was added. The reaction mixtures were then incubated at 37±2 °C in an incubator for 15 min and then heated at 70°C for 5 min in a hot water bath. After cooling down, the absorbance was measured at 660 nm against blank. A similar volume of distilled water served as control. Diclofenac sodium in the final concentration of 50-400 µg/ml was used as reference drug. The %age inhibition of protein denaturation was calculated from the following formula:

$$\% \text{ inhibition} = 100 \times [A_T / A_C - 1]$$

where, A_T = absorbance of test sample, A_C = absorbance of control. The experiment was done in triplicate and the average was taken.

***In silico* prediction of bioactivity and molecular docking studies**

Bioactivity potential of the major chemical constituent presents in the CEO was predicted with the help of PASS (Prediction of activity spectra for substances) prediction [24]. Molecular docking studies of the selected phytocompounds were also performed on Autodock vina [25] using enzyme Human peroxiredoxin 5 (PDB ID: 1HD2) [26] and anti-inflammatory protein, Human Cyclooxygenase-2 (5IKQ) [27] in order to know the binding affinity and various ligands. Both the proteins were retrieved from protein data bank (<https://www.rcsb.org/>) in pdb format. Ascorbic acid and Tocopherol were used as standard drug for antioxidant protein target, while Arachidonic acid and Diclofenac were used as standard drug for inflammatory protein target. Lipinski's rule [28], [29] (rule of five, RO5) was to evaluate the drug-likeness property. The admet SAR [30], [31] and Protox-II server [32] were used to predict ADME and toxicity respectively. Detailed visualization and comparison of the docked sites of target proteins and ligands were done by Chimera [33] and LigPlot [34].

Statistical analysis

The data was expressed as mean $\pm$ standard deviation, calculated using Microsoft Office Excel. The experiments were performed in triplicate and their average mean was calculated. IC_{50} values were calculated from the linear regression method.

Results

Percentage yield and chemical composition of CEO

The percentage yield of essential oil from fresh leaves was $0.16 \pm 0.086\%$. GC-MS analysis of the essential oil of *C. citratus* showed the presence of 48 phytocompounds. These phytocompounds were identified by comparing the mass spectra of the constituents with the NIST mass spectral library (<https://chemdata.nist.gov/>) and are summarized in table 1. The mass spectra of all the phytochemicals identified in the essential oil of *C. citratus* are presented in Fig.1. Among all phytocompounds, 8-methyl-3,7-Nonadien-2-one (E) (27.28%), α -Pinene (15.60%), limonene (4.88%), citral (4.87%), limonene oxide (4.27%) and Epoxy- α -terpenyl acetate (4.03%) were major constituents, contribute 66.66% of total volatile

constituents. The structures of major phytocompounds were drawn through ChemDraw software and were shown in Fig. 2.

Fig. 1: Chemical composition of CEO using GC-MS analysis.

Table 1: Phytocompounds identified in CEO using GC-MS analysis.

Compound name	RT	Area percentage
Cyclohexane	3.32	3.05
1-Phenyl-5-methylheptane	4.35	0.009
3-Penten-2-one, 4-methyl-	5.02	0.12
2-Pentanone, 4-hydroxy-4-methyl-	6.24	1.59
4-Methyl-3-hexanol acetate	6.56	0.12
3-Hexen-1-ol, (Z)-	6.67	0.14
3-Pentanone, 2,4-dimethyl-	7.08	0.08
α -Phellandrene	8.41	0.40
Bicyclo[3.1.0]hex-2-ene, 2-methyl-5-(1-methylethyl)	8.69	0.50
Camphene	9.08	2.27
α -Pinene	10.22	15.60
Limonene	10.85	4.88
3-Carene	11.13	1.84
4-Nonanone	11.55	1.01
Bicyclo[4.1.0] heptan-3-one,	11.91	0.35
Epoxy- α -terpenyl acetate	12.18	4.03
Linalyl acetate	12.80	0.11
Carane, 4,5-epoxy-, trans	13.18	3.73
3-Cyclohexene-1-carboxaldehyde,	13.43	3.15

1,3,4-trimethyl		
(+)-(E)-Limonene oxide	13.66	4.27
cis-Verbenol	13.98	2.05
Citral	14.39	4.87
3,7-Nonadien-2-one, 8-methyl-, (E)-	15.98	27.28
Cyclohexanone, 2-methylene-5-(1-methylethyl)-	16.28	1.05
Phenol, 2-methoxy-4-(2-propenyl)-, acetate	16.45	0.55
Isopulegol	16.61	2.49
D-Verbenone	16.81	0.59
Caryophyllene	17.31	3.83
Humulene	17.68	0.45
2-Nonanone, 9-hydroxy-	17.93	0.86
α -Bisabolene	18.16	0.07
(+)-epi-Bicyclo sesquiphellandrene	18.32	1.25
Ginsenoside	18.49	0.20
Cyclohexanemethanol,4-ethenyl- α,α ,4-trimethyl-3-(1-methylethenyl)-,[1R-(1 α ,3 α ,4 α)]-	18.68	0.49
Caryophyllene oxide	19.18	2.70
Spiro[4.5]decane	19.47	0.43
Agarospirol	19.60	1.13
Cyclohexanemethanol,4-ethenyl- α,α ,4-trimethyl-3-(1-methylethenyl)-,[1R-(1 α ,3 α ,4 α)]-	19.96	0.16
1-Naphthalenol,decahydro-1,4a-dimethyl-7-(1-methylethylidene)-,[1R-(1 α ,4 $\alpha\alpha$,8 $\alpha\alpha$)]-	20.09	0.36
(-)-Globulol	20.45	0.22
2,6,10-Dodecatrienal, 3,7,11-trimethyl-, (E,E)-	20.74	0.18
3,7,11,15-Tetramethyl-2-hexadecen-1-ol	21.80	0.30
Geranic acid	22.41	0.07
(E,E)-7,11,15-Trimethyl-3-methylene-hexadeca-1,6,10,14-tetraene	22.98	0.06
p-Heptylacetophenone	24.51	0.46
1,2-Oxaborole,2,3,4-triethyl-2,5-dihydro-5,5dimethyl-	24.77	0.31
Methyl Camphorsulfonates	26.94	0.08
Cyclohexene,1-formyl-2-phenylsulfinylmethyl-3,3-dimethyl-	27.31	0.19
Total identified		99.879%

Fig. 2: Structure of important phytochemicals identified in GC-MS analysis of CEO.

Analysis of antioxidant activity of CEO

Essential oil of *C. citratus* (CEO) leaves followed dose-dependent pattern for all antioxidant assays (DPPH, ABTS and FRAP) as shown in Fig. 3A, B, C. IC₅₀ of CEO was found to be $91.0 \pm 9.25 \mu\text{g ml}^{-1}$, $350.957 \pm 8.92 \mu\text{M}$, and $370.2 \pm 11.81 \mu\text{g ml}^{-1}$, with DPPH, FRAP and ABTS assay, respectively indicating strong DPPH radical scavenging activity as compared to FRAP and ABTS activity. Ascorbic acid showed IC₅₀ value of $33.38 \pm 2.29 \mu\text{g ml}^{-1}$, $157.26 \pm 19.09 \mu\text{M}$ and $170.41 \pm 7.91 \mu\text{g ml}^{-1}$, respectively with DPPH, FRAP and ABTS method (Table-2).

Fig. 3: Concentration dependent antioxidant activity of CEO using DPPH radical scavenging assay (A), ABTS scavenging activity (B) and FRAP assay (C).

Table-2: Half maximal inhibitory concentration (IC₅₀) of CEO. Ascorbic acid was used as positive control. Values are expressed as mean $\pm$ S.D. of three independent experiments.

Antioxidant assays	IC ₅₀ value	
	Ascorbic acid	CEO
DPPH*	33.38 $\pm$ 2.29	91.0 $\pm$ 9.25
FRAP**	157.26 $\pm$ 19.09	350.957 $\pm$ 8.92
ABTS*	170.41 $\pm$ 7.91	370.1985 $\pm$ 11.81

*- μ g/ml; **- μ M Fe (II) equivalents

Anti-inflammatory activity of CEO

In vitro anti-inflammatory activity of CEO was determined by denaturation of egg albumin using different concentrations (50-400 μ g ml⁻²) of CEO and diclofenac sodium and it showed concentration-dependent pattern of denaturation. It was observed that CEO was found to exhibit strong inflammatory activity (IC₅₀-397.11 $\pm$ 1.45 μ g/ml) as compared to diclofenac (IC₅₀-682.98 $\pm$ 7.47 μ g/ml) (Fig. 4).

Fig. 4: *In vitro* anti-inflammatory activity of CEO using egg albumin denaturation. Diclofenac sodium was used as control.

Receptor-ligands interactions

Cyclooxygenase plays a major role in inflammation and is responsible for conversion of arachidonic acid to prostaglandins. It exists in two isoforms- cyclo oxygenase-1 which is constitutive and cyclo oxygenase-2 (COX-2) which is induced by cytokines [35]. Selective inhibitors of COX-2 also increase the risk of vascular events [36]. Human PRDX5 antioxidant enzyme permits the reduction of hydrogen peroxide and alkyl peroxide, with the help of thiol -containing donor molecules [37, 38]. The results of docking interaction between selected phytocompounds and targeted receptor proteins, Human peroxiredoxin 5(1HD2) and Human Cyclooxygenase-2 (5IKQ) were shown in Table 3. It was found that β -Caryophyllene showed best interaction with 1HD2 with docking score ($-7.9 \text{ kcal mol}^{-1}$) followed by caryophyllene oxide ($-7.1 \text{ kcal mol}^{-1}$) as compared to α -Tocopherol ($-7.3 \text{ kcal mol}^{-1}$) and ascorbic acid ($-4.9 \text{ kcal mol}^{-1}$). Similarly, caryophyllene oxide (-10.3 kcal/mol) and β -Caryophyllene ($-10.2 \text{ kcal mol}^{-1}$) showed highest binding energy as compared to that of diclofenac ($-8.7 \text{ kcal mol}^{-1}$) and arachidonic acid $-7.0 \text{ kcal mol}^{-1}$) (Table 3). The interacting amino acids showing H-bonding and hydrophobic interaction between phytocompounds and receptors were shown in table 3. Interactions of both the receptors with caryophyllene oxide and β -Caryophyllene were shown in Fig. 5 and 6.

LigPlot structures of all the selected phytocompounds with both the target receptors were shown in supplementary data (Supplementary Fig. 1 and Supplementary Fig. 2).

Table 3: Binding energy calculated through Autodock vina and interactions of phytochemicals and selected drugs with target protein receptors. Diclofenac and Arachidonic acid were used as standard control with 5IKQ, while Ascorbic acid and α -Tocopherol were used as standard control with 1HD2 receptor.

Compounds/Drugs	1HD2			5IKQ		
	Affinity (kcal/mol)	H-bonding	Non-covalent interactions	Affinity (kcal/mol)	H-bonding	Non-covalent interactions
3,7-Nonadien-2-one, 8-methyl-, (E)-	-4.5	Ser 115(A)	Asp 113(A), Leu 116(A), Leu 112(A), Thr 147(A)	-6.4	-	Leu 352(A), Ser 353(A), Trp 387(A), Phe 518(A), Val 523(A), Gly 526(A), Leu 384(A), Tyr 385(A), Met 522(A)
α -pinene	-5.0	-	Pro 40(A), Pro 45(A), Leu 116(A), Ile 119(A), Phe 120(A), Thr 44(A), Thr 147(A)	-6.7	-	Gln 203(A), Tyr 385(A), Trp 387(A), Leu 390(A), Ala 199(A), Ala 202(A), Leu 391(A)
Limonene	-5.1	-	Phe 15(A), Pro 19(A), Ala 78(A), Pro 100(A)	-7.8	-	Phe 209(A), Ser 530(A), Leu 534(A), Phe 205(A), Phe 381(A), Gly 533(A), Gly 227(A), Val 228(A), Asn 375(A), Ile 377(A)
Citral	-4.6	Thr 147(A)	Phe 43(A), Val 80(A), Leu 149(A), Gly 46(A), Ala 42(A), Asn 76(A), Glu 83(A)	-6.3	Thr 206(A)	Trp 387(A), Gln 203(A), Ala 202(A), Ala 199(A), Tyr 385(A), Leu 390(A), His 207(A), Leu 391(A)
Epoxy- α -terpenyl acetate	-5.5	-	Pro 40(A), Thr 147(A), Leu 116(A), Phe 120(A), Thr 44(A), Ile 119(A), Arg 127(A)	-7.9	-	Val 523(A), Leu 352(A), Gly 526(A), Ser 353(A), Phe 518(A), Met 522(A), Ala 527(A), Trp 387(A)
β -Caryophyllene	-7.9	-	Pro 19(A), Asp 77(A), Ala 78(A), Pro 100(A), Phe 15(A)	-10.2	-	Val 523(A), Phe 381(A), Leu 384(A), Tyr 385(A), Trp 387(A), Met 522(A), Ala 527(A), Ser 530(A), Gly 526(A), Phe 518(A)
Carane, 4,5-epoxy-, trans	-5.5	-	Phe 15(A), Pro 19(A), Asp 77(A), Ala 78(A), Pro 100(A)	-7.7	Trp 387(A)	Leu 391(A), Ala 199(A), Ala 202(A), Leu 390(A), Tyr 385(A)
3-Cyclohexene-1-carboxaldehyde, 1,3,4-trimethyl	-5.7	Ala 78(A)	Pro 19(A), Asp 77(A), Pro 100(A), Phe 15(A)	-7.2	-	Gln 203(A), Tyr 385(A), Ala 202(A), Ala 199(A), Thr 206(A), Trp 387(A), Leu 390(A)
Cyclohexane	-4.1	-	Pro 19(A), Phe 15(A), Asp 77(A), Ala 78(A), Pro 100(A)	-5.3	-	Ser 530(A), Phe 205(A), Phe 209(A), Phe 381(A), Gly 533(A), Leu 534(A), Val 228(A)
Caryophyllene oxide	-7.1	-	Pro 40(A), Thr 147(A), Thr 44(A), Phe 120(A), Pro 45(A), Leu 116(A), Ile 119(A)	-7.2	-	Tyr 385(A), Phe 518(A), Val 523(A), Val 349(A), Phe 381(A), Leu 384(A), Trp 387(A), Ser 530(A), Gly 526(A), Ala 527(A), Met 522(A)

Isopulegol	-5.1	-	Phe 15(A), Pro 19(A), Ala 78(A), Pro 100(A), Asp 77(A)	-7.2	Tyr 385(A), Trp 387(A)	Ala 202(A), Gln 203(A), Ala 199(A), Thr 206(A), Leu 391(A)
Camphene	-5.2	-	Pro 19(A), Asp 77(A), Ala 78(A), Pro 100(A), Phe 15(A)	-7.0	-	Phe 381(A), Leu 384(A), Tyr 385(A), Trp 387(A), Met 522(A), Ser 530(A), Gly 526(A), Phe 518(A), Val 523(A), Leu 352(A)
Cis-verbenol	-5.0	-	Phe 15(A), Pro 19(A), Asp 77(A), Ala 78(A), Pro 100(A)	-7.2	-	Phe 518(A), Met 522(A), Leu 352(A), Leu 384(A), Tyr 385(A), Trp 387(A), Val 523(A), Ser 530(A), Gly 526(A)
Diclofenac	-	-	-	-8.7	-	Tyr 385(A), Trp 387(A), His 388(A), Leu 391(A), Thr 206(A), His 207(A), Ala 202(A), Gln 203(A), Leu 390(A)
Arachidonic acid	-	-	-	-7.0	Tyr 355(A)	Tyr 385(A), Arg 120(A), Val 349(A), Leu 352(A), Ser 353(A), Trp 387(A), Phe 518(A), Ala 527(A), Ser 530(A), Met 522(A), Gly 526(A), Val 523(A)
Ascorbic acid	-4.9	Asn 122(A), Asp 77(A), Arg 124(A), Asn 76(A)	Pro 100 (A), Val 75(A)	-	-	-
α -Tocopherol	-7.2	Arg 127(A)	Asp 113(A), Thr 147(A), Leu 116(A), Ser 115(A), Leu 112(A), Pro 40(A), Thr 44(A), Gly 46(A), Cys 47(A), Phe 120(A), Asp 145(A)	-	-	-

Fig. 5: Interactions of Human Peroxiredoxin receptor with caryophyllene oxide (A), β -caryophyllene (B), ascorbic acid (C) and α -Tocopherol (D). Amino acids with hydrophobic interactions were shown in orange red color, whereas, amino acids showing H-bonding with receptor were shown in blue color.

Fig. 6: Interactions of Human Cyclooxygenase-2 receptor with caryophyllene oxide (A), β -caryophyllene (B), Diclofenac (C) and Arachidonic acid (D). Amino acids with hydrophobic interactions were shown in orange red color, whereas, amino acids showing H-bonding with receptor were shown in blue color.

Drug likeness prediction of selected phytochemicals of CEO

The drug likeness filters help in the early preclinical development by avoiding costly late step preclinical and clinical failure. The drug likeness properties of phytochemicals showing good interactions (α -Pinene, Limonene, (+)-(E)-Limonene oxide, Isopulegol, Caryophyllene oxide) were analyzed based on the Lipinski rule of 5. It was found that all the selected phytochemicals followed Lipinski's rule of five (Table 4).

Table 2: Drug-likeness prediction of selected phytochemicals from *C. citratus*

Compounds	SWISS ADME							Lipinski rule
	Log P	Polar Surface Area (A2)	No. of atoms	No. of Nitrogen and Oxygen	No. of OH and -NHn	nviolations	MW	
α -Pinene	3.54	0	10	0	0	0	136.23	Yes
Limonene	3.62	0	10	0	0	0	136.24	Yes
(+)-(E)-Limonene oxide	2.81	12.53	11	1	0	0	152.24	Yes
β -Caryophyllene	5.17	0.00	15	0	0	1	204.36	Yes
Caryophyllene oxide	4.14	12.53	16	1	0	0	220.35	Yes
Isopulegol	2.65	20.23	11	1	1	0	154.25	Yes
Diclofenac	4.57	49.33	19	3	2	0	296.15	Yes
Arachidonic acid	6.42	37.30	22	2	1	1	304.47	Yes
α -Tocopherol	9.04	29.46	31	2	1	1	430.72	Yes
Ascorbic acid	-1.40	107.22	12	6	4	0	176.12	Yes

3.3 Toxicity and ADME/T prediction of phytochemicals of *C. citratus*

The results of admetSAR analysis and toxicity prediction were shown in table 5. All of the phytochemicals showed an acceptable range of ADME/T profiles that reflect their efficiency as potent drug candidates. All the compounds showed good human intestinal solubility (HIA) and are non-carcinogenic in nature. Rat acute toxicity concentration of all the compounds was high, indicating low toxicity (Table 5). Rodent toxicity (LD₅₀) values for all selected compounds were

higher, indicating non-toxic nature of these compounds. Also, these compounds were non-cytotoxic and non-hepatotoxic except α -Pinene (Table 3).

Table-3: ADMET and Protox-II prediction of selected phytochemicals of *C. citratus* and drugs used through admetSAR and Protox-II software.

Compounds/ drugs	admet SAR			Protox II		
	Human intestinal absorption	Carcinogens	Rate Acute Toxicity (LD ₅₀) kg/mol	LD ₅₀ (mg kg ⁻¹)	Hepatotoxicity	Cytotoxicity
α -Pinene	Positive	Non- Carcinogens	1.527 (III)	1190 (class 4)	Active	Inactive
Limonene	Positive	Non- Carcinogens	1.856 (III)	4400 (class 5)	Inactive	Inactive
(+)-(E)- Limonene oxide	Positive	Non- Carcinogens	1.438 (III)	5000 (class 5)	Inactive	Inactive
β - Caryophyllene	Positive	Non- Carcinogens	2.366 (III)	5000 (class 5)	Inactive	Inactive
Caryophyllene oxide	Positive	Non- Carcinogens	2.236 (III)	5000 (class 5)	Inactive	Inactive
Isopulegol	Positive	Non- Carcinogens	2.923 (III)	2000 (class 4)	Inactive	Inactive
Diclofenac	Positive	Non- Carcinogens	3.029 (II)	53 (class 3)	Active	Inactive
Arachidonic acid	Positive	Non- Carcinogens	1.782 (IV)	10000 (class 6)	Inactive	Inactive
α -Tocopherol	Positive	Non- Carcinogens	2.47 (III)	5000 (class 5)	Inactive	Inactive
Ascorbic acid	Positive	Non- Carcinogens	0.481 (IV)	3367 (class 5)	Inactive	Inactive

3.4 *In silico* PASS prediction of selected phytochemicals of CEO

The selected phytochemicals of CEO were evaluated for their anti-inflammatory and antioxidant spectra, and results of PASS prediction was shown in table 4. In the case of anti-

inflammatory activity, all the compounds showed greater P_a than 0.5, except α -Pinene. Caryophyllene oxide and β -Caryophyllene showed highest P_a value of 0.759 and 0.745; while in case of antioxidant activity, all the selected phytocompounds showed $P_a < 0.5$. Among all compounds, Isopulegol and β -Caryophyllene showed highest P_a value of 0.184 and 0.174 respectively (Table 4).

Table 4: *In silico* PASS prediction for anti-inflammatory and antioxidant activity of selected phytocompounds of CEO.

Phytocompounds/drugs	Anti-inflammatory		Antioxidant	
	P_a	P_i	P_a	P_i
α -Pinene	0.490	0.060	-	-
Limonene	0.610	0.029	0.157	0.094
Limonene oxide	0.654	0.022	0.153	0.099
β -Caryophyllene	0.745	0.011	0.174	0.074
Caryophyllene oxide	0.759	0.009	0.144	0.110
Isopulegol	0.690	0.017	0.184	0.066
Diclofenac	0.791	0.007	-	-
Arachidonic acid	0.730	0.012	-	-
α -Tocopherol	-	-	0.967	0.002
Ascorbic acid	-	-	0.928	0.003

CEO= Essential oil of *C. citratus* leaves; P_a = Probable activity; P_i = probable inactivity; PASS = Prediction of Activity Spectra for Substances

Discussions

Traditional medicines play paramount role to cure different diseases. The plants utilized as a medicine from pre-historic time plays consequential role in primary health care. Medicinal plant contains variants of secondary metabolites which are responsible for pharmacological activities [39]. Several previous reports showed the use of plant as medicine to cure inflammation exhibiting antioxidant and anti-inflammatory activities [40]. Antioxidant compounds have been reported to obviate oxidative stress of free radicals associated with pathogenesis of a number of chronic diseases including diabetes and inflammation [41]. In present investigation, we have reported 48 phytocompounds in essential oil of *C. citrates*, out of which, 8-methyl-3,7-Nonadien-2-one (E) (27.28%) was the major constituents.

Several studies have been reported chemical composition of essential oil from *C. citrates* and found geranial, neral, and myrcene as major components [42-50]. Similar results were also reported by Hanna et al. [51] while investigating the effect of drying method on chemical composition of essential oil of lemon grass; however, there was variation in number of components, but components were same with all drying methods. Longifolene-(V4) (56.67%) and selina-6-ezn-4-ol (20.03%) was found to be major constituents in essential oil obtained from roots of *C. citratus* [52]. This variation in essential oil from *C. citratus* may be attributed to different geographical location, climate conditions, harvest period, plant age and distillation method [53-54].

Antioxidants play an important role in the prevention and promotion of health in humans against the harmful free radicals that cause many age-related diseases. Similar to our report, Farias et al. [55] also found low antioxidant capacity of essential oil from *C. citratus*. There are several studies, which showed good antioxidant potential of essential oil from *C. citratus* [43], [56-59]. In addition to essential oil, several reports have described the antioxidant potential of various extracts of *C. citratus* [60-62]. The essential oil of *C. citratus* showed strong anti-inflammatory activity as compared to standard drug, Diclofenac sodium. Anti-inflammatory activity of *C. citratus* was due to the presence of luteolin glycosides [63-64]. *In vivo* topical and oral anti-inflammatory potential of lemon grass essential oil was also reported by Boukhatem et al. [65] using carrageenan-induced paw edema test and croton oil-induced ear edema in mouse model. Costa et al. [66] also reported promising topical anti-inflammatory activity of *C. citratus* infusion, containing luteolin 7-*O*-neohesperidoside, cassiaoccidentalin B, carlinoside, cynaroside and tannins. Molecular docking study with antioxidant Human peroxiredoxin 5 (PDB ID: 1HD2) and anti-inflammatory protein, Human Cyclooxygenase-2 (PDB ID: 5IKQ) receptor showed that among all selected major phytochemicals, caryophyllene showed best interaction with 1HD2 with binding energy (-7.9 kcal/mol) which is higher than tocopherol (-7.3 kcal/mol) and ascorbic acid (-4.9 kcal/mol). Similarly, with 5IKQ, caryophyllene oxide and caryophyllene showed highest binding energy (-10.3 and -10.3 kcal/mol respectively) as compared to that of diclofenac (-8.7 kcal/mol) and arachidonic acid -7.0 kcal/mol). Both the phytochemicals also qualify ADMET features. These compounds were found to be safe by admetSAR and Protox-II software and also show highest P_a value with anti-inflammatory. The present study is an attempt showing

anti-inflammatory and antioxidant activity of CEO through *in vitro* method and inhibitory action of phytochemicals of CEO against cyclooxygenase 2 and human peroxiredoxin proteins.

Conclusion

C. citratus is one of the important herbs which play an important role in human health due to the presence of phytochemicals which are responsible for its biological activity. However, the quantification of these phytochemicals in *C. citratus* is affected by geographical and climatic conditions. In the current investigation, CEO was examined for its chemical composition, *in vitro* antioxidant and anti-inflammatory activity, to provide a justification of its health benefits. CEO exhibit good DPPH radical scavenging activity, while FRAP and ABTS activity of CEO was very low which may be due to combined effect of several phytochemicals. However, CEO showed significant anti-inflammatory activity. *In silico* prediction and molecular docking studies showed that Caryophyllene oxide and β -Caryophyllene contributed to antioxidant and anti-inflammatory activity of CEO. However, except α -Pinene (hepatotoxic), all the phytochemicals were found to qualify ADME/T condition and are less toxic in nature. In a nutshell, the present study opens new avenues for the plant *C. citratus* to be used as safe and less toxic alternatives to synthetic drugs used in complications arising due to oxidative stress and inflammation.

References

1. B. Ali, N.A. Al-Wabel, S. Shams, A. Ahamad, S.A. Khan, F Anwar Essential oils used in aromatherapy: A systemic review. Asian Pac, J Trop Biomed 5(8) (2015) 601-611.
2. G. Shrivastava, M. Rogers, A. Wszelaki, D.R. Panthee, F. Chen Plant volatiles-based insect pest management in organic farming, Crit Rev Plant Sci 29(2) (2010)123-133.
3. K. Aftab, M.D. Ali, P. Aijaz, N. Beena, H.J. Gulzar, K. Sheikh, Q. Sofia Tahir Abbas S. Determination of different trace and essential element in lemon grass samples by x-ray fluorescence spectroscopy technique, Int Food Res J 18(1) (2011) 265-270.
4. P.A. Tarkang, G.A. Agbor, N. Tsabang, L.R. Tchokouaha, D.A. Tchamgoue, D. Kemeta, Y.S. Mengue, J.R. Mba, F. Weyepe Effect of long-term oral administration of the aqueous and ethanol leaf extracts of *Cymbopogon citratus* (DC. ex Nees) Stapf, Ann Biol Res 3(12) (2012) 5561-70.

5. R.P. Pereira, R. Fachinetto, A. de Souza Prestes, R.L. Puntel, G.N. Da Silva, B.M. Heinzmann, T.K. Boschetti, M.L. Athayde, M.E. Bürger, A.F. Morel, V.M. Morsch Antioxidant effects of different extracts from *Melissa officinalis*, *Matricaria recutita* and *Cymbopogon citratus*, *Neurochem Res* 34(5) (2009) 73-83.
6. B. Wannissorn, S. Jarikasem, T. Siriwangchai, S. Thubthimthed Antibacterial properties of essential oils from Thai medicinal plants, *Fitoterapia* 76(2) (2005) 233-6.
7. E.A. Carlini, J.D. Contar, A.R. Silva-Filho, N.G. Da Silveira-Filho, M.L. Frochtengarten, O.F. Bueno Pharmacology of lemongrass (*Cymbopogon citratus* Stapf). I. Effects of teas prepared from the leaves on laboratory animals, *J Ethnopharmacol* 17(1) (1986) 37-64.
8. O.S. Oladeji, F.E. Adelowo, D.T. Ayodele, K.A. Odelade Phytochemistry and pharmacological activities of *Cymbopogon citratus*: a review, *Scientific African* 6 (2019) e00137.
9. N.I. Anggraeni, I.W. Hidayat, S.D. Rachman, Ersanda Bioactivity of essential oil from lemongrass (*Cymbopogon citratus* Stapf) as antioxidant agent. In AIP Conference Proceedings 1927(1) (2018) 030007.
10. K. Gayathri, K.S. Jayachandran, H.R. Vasanthi, G.V. Rajamanickam Cardioprotective effect of lemon grass as evidenced by biochemical and histopathological changes in experimentally induced cardiotoxicity, *Hum Exp Toxicol* 30(8) (2011) 1073-1082.
11. R.R. Negrelle, E.C. Gomes *Cymbopogon citratus* (DC.) Stapf: chemical composition and biological activities, *Rev Bras Plantas Med* 9(1) (2007) 80-92.
12. M. Tognolini, E. Barocelli, V. Ballabeni, R. Bruni, A. Bianchi, M. Chiavarini, M. Impicciatore Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity, *Life Sci* 78(13) (2006) 1419-32.
13. M.A. Mansour, M.N. Nagi, A.S. El-Khatib, A.M. Al-Bekairi Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action, *Cell Biochem Funct* 20(2) (2002) 43-51.
14. F. Tchoumboungang, P.A. Zollo, F.F. Boyom, M.A. Nyegue, J.M. Bessière, C. Menut Aromatic plants of tropical Central Africa. XLVIII. Comparative study of the essential

oils of four Hyptis species from Cameroon: *H. lanceolata* Poit., *H. pectinata* (L.) Poit., *H. spicigera* Lam. and *H. suaveolens* Poit, Flavour Fragr J 20(3) (2005) 340-3.

15. R.R. Negrelle, E.C. Gomes *Cymbopogon citratus* (DC.) Stapf: chemical composition and biological activities, Rev Bras Pl Med 9(1) (2007) 80-92.
16. O. Avoseh, O. Oyedeji, P. Rungqu, B. Nkeh-Chungag, A. Oyedeji A *Cymbopogon* species; ethnopharmacology, phytochemistry and the pharmacological importance, Molecules 20(5) (2015) 7438-53.
17. R.J.W. Lambert, P.N. Skandamis, P.J. Coote, G.J. Nychas A study of the minimum inhibitory concentration and mode of action of oregano essential oil, thymol and carvacrol, J Appl Microbiol 91(3) (2001) 453-462.
18. L. Barros, R.C. Calhelha, J.A. Vaz, I.C. Ferreira, P. Baptista, L.M. Estevinho Antimicrobial activity and bioactive compounds of Portuguese wild edible mushrooms methanolic extracts, Eur Food Res Tech 225(2) (2007) 151-6.
19. R. Rolta, A. Sharma, V. Kumar, A. Sourirajan, D.J. Baumler, K. Dev. Methanolic extracts of the rhizome of *R. emodi* act as bioenhancer of antibiotics against bacteria and fungi and antioxidant potential, J Med Plant Res 28(8) (2018) 74-85.
20. I.F. Benzie, J.J. Strain. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay, Anal Biochem 239(1) (1996) 70-6.
21. R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang, C. Rice-Evans Original Contributions-Antioxidant activity applying an improved ABTS radical cation decolorization assay, Free Radic Biol Med 26(9) (1999) 1231-7.
22. S. Chandra, P. Dey, S. Bhattacharya Preliminary in vitro assessment of anti-inflammatory property of *Mikania scandens* flower extract, J Adv Pharm Edu Res 2(1) (2012) 25-31.
23. R. Gogoi, R. Loring, N. Sarma, S. Munda, S.K. Pandey, M.A. Lal Comparative study on antioxidant, anti-inflammatory, genotoxicity, anti-microbial activities and chemical composition of fruit and leaf essential oils of *Litsea cubeba* Pers from North-east India, Ind Crops Prod 125 (2018) 31-9.

24. L.S. Nath, S.A. Khan, A. Ahmad Research Article Computer aided screening of natural products in search of lead molecules for design and development of potent anti-inflammatory agents, *Sch Acad J Pharm* 3(6) (2014) 496-503
25. O. Trott, A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, *J Comput Chem* 31(2) (2010) 455-461.
26. J.P. Declercq, C. Evrard A twinned monoclinic crystal form of human peroxiredoxin 5 with eight molecules in the asymmetric unit, *Acta Crystallogr D* 57(12) (2001) 1829-35.
27. B.J. Orlando, M.G. Malkowski Substrate-selective inhibition of cyclooxygenase-2 by fenamic acid derivatives is dependent on peroxide tone, *J Biol Chem* 291(29) (2016) 5069-81.
28. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv Drug Deliv Rev* 23(1-3) (1997) 3-25.
29. C.A. Lipinski Lead-and drug-like compounds: the rule-of-five revolution, *Drug Discov Today Technol* 1(4) (2004) 337-341.
30. F. Cheng, W. Li, Y. Zhou, J. Shen, Z. Wu, G. Liu, G. Liu, W.L. Philip, Y. Tang admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties, *J Chem Inf Model* 52(11) (2012) 3099-3105.
31. H. Yang, C. Lou, L. Sun, J. Li, Y. Cai, Z. Wang, W. Li, G. Liu, Y. Tang admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties, *Bioinformatics* 35(6) (2019) 1067-1069.
32. P. Banerjee, A.O. Eckert, A.K. Schrey, R. Preissner ProTox-II: a webserver for the prediction of toxicity of chemicals. *Nucleic Acids Res.*, 46(W1) (2018), W257-W263.
33. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin UCSF Chimera—a visualization system for exploratory research and analysis, *J Comput Chem* 25(13) (2004) 1605-12.

34. R.A. Laskowski, M.B. Swindells LigPlot+: multiple ligand–protein interaction diagrams for drug discovery, *J Chem Inf Model* 51(10) (2011) 2778-2786.
35. K. Seibert, J. Masferrer, Y. Zhang, S. Gregory, G. Olson, S. Hauser, K. Leahy, W. Perkins, P. Isakson Mediation of inflammation by cyclooxygenase-2, *Agents Actions Suppl* 46 (1995) 41-50.
36. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials *BMJ* 332 (2006) 1302-1308.
37. J.P. Declercq, C. Evrard,, A. Clippe, D. Vander Stricht, A. Bernard, B . Knoops, Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 Å resolution, *J. Mol. Biol.* 311 (2001) 751 -759.
38. H.A. Khamees, Y.H. Mohammed, A. Swamynayaka, F.H. Al -Ostoot, Y. Sert, S . Alghamdi, M. Madegowda, Molecular structure, DFT, vibrational spectra with fluorescence effect, hirshfeld surface, docking simulation and antioxidant activity of thiazole derivative, *Chemistry Select .* 4 (2019) 4544 -4558
39. Z.Q. Shi, D.F. Song, R.Q. Li, H. Yang, L.W. Qi, G.Z. Xin, D. Wang Identification of effective combinatorial markers for quality standardization of herbal medicines, *J Chromatogr A* 1345 (2014) 78-85.
40. N.P. Babu, P. Pandikumar, S. Ignacimuthu Anti-inflammatory activity of *Albizia lebbeck* Benth., an ethnomedicinal plant, in acute and chronic animal models of inflammation, *J Ethnopharmacol* 125(2) (2009) 356-360.
41. J.L. Evans, I.D. Goldfine, B.A. Maddux, G.M. Grodsky Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes, *Endocr Rev* 23(5) (2002) 599-622.
42. E.H. Chisowa, D.R. Hall Volatile constituents of the essential oil of *Cymbopogon citratus* Stapf grown in Zambia, *Flavour Fragr J* 13(1) (1998) 29-30.

43. C. Menut, J.M. Bessiere, D. Samate, A.K. Djibo, G. Buchbauer, B. Schopper Aromatic plants of tropical west Africa. XI. Chemical composition, antioxidant and antiradical properties of the essential oils of three *Cymbopogon* species from Burkina Faso. *J. Essent. Oil Res.*, 12(2) (2000), pp. 207-12.
44. A.A. Kasali, A.O. Oyedeji, A.O. Ashilokun Volatile leaf oil constituents of *Cymbopogon citratus* (DC) Stapf, *Flavour Fragr J* 16(5) (2001) 377-378.
45. L. Sidibé, J.C. Chalchat, R.P. Garry, L. Lacombe, M. Harama Aromatic plants of Mali (IV): chemical composition of essential oils of *Cymbopogon citratus* (DC) Stapf and *C. giganteus* (Hochst.) Chiov, *J Essent Oil Res* 13(2) (2001) 110-112.
46. G. Sacchetti, S. Maietti, M. Muzzoli, M. Scaglianti, S. Manfredini, M. Radice, R. Bruni Comparative evaluation of 11 essential oils of different origin as functional antioxidants, antiradicals and antimicrobials in foods, *Food Chem* 91(4) (2005), 621-32.
47. V.C. Oliveira, D.M. Moura, J.A. Lopes, P.P. de Andrade, N.H. da Silva, R.C. Figueiredo Effects of essential oils from *Cymbopogon citratus* (DC) Stapf., *Lippia sidoides* Cham., and *Ocimum gratissimum* L. on growth and ultrastructure of *Leishmania chagasi* promastigotes, *Parasitol Res* 104(5) (2009) 1053-9.
48. J. Olivero- Verbel, L.S. Nerio, E.E. Stashenko Bioactivity against *Tribolium castaneum* Herbst (Coleoptera: Tenebrionidae) of *Cymbopogon citratus* and *Eucalyptus citriodora* essential oils grown in Colombia, *Pest Manag Sci* 66(6) (2010) 664-668.
49. I.H. Bassolé, A. Lamien-Meda, B.O. Bayala, L.C. Obame, A.J. Ilboudo, C. Franz, J. Novak, R.C. Nebié, M.H. Dicko Chemical composition and antimicrobial activity of *Cymbopogon citratus* and *Cymbopogon giganteus* essential oils alone and in combination, *Phytomedicine* 18(12) (2011) 1070-4.
50. M.N. Boukhatem, A. Ferhat, A. Kameli, F. Saidi, H.T. Kebir Lemon grass (*Cymbopogon citratus*) essential oil as a potent anti-inflammatory and antifungal drugs, *Libyan J Med* 9(1) (2014) 25431.
51. A.M. Hanaa, Y.I. Sallam, A.S. El-Leithy, S.E. Aly Lemongrass (*Cymbopogon citratus*) essential oil as affected by drying methods, *Ann Agric Sci* 57(2) (2012) 113-116.

52. D. Ganjewala, D Cymbopogon essential oils: Chemical compositions and bioactivities, Int J Essen Oil Ther 3(2-3) (2009) 56-65.
53. E.O. Akinkunmi, A. Oladele, O. Esho, I. Odusegun Effects of storage time on the antimicrobial activities and composition of lemon grass oil, J Appl Res Med Aroma 3(3) (2016) 105-111.
54. M.M. Ali, M.A. Yusuf, M.N. Abdalaziz GC-MS Analysis and antimicrobial screening of essential oil from lemongrass (*Cymbopogon citratus*), Int J Pharm Chem Anal 3(6) (2017) 72-76.
55. P.K. Farias, J.C. Silva, C.N. Souza, F.S. Fonseca, I.V. Brandi, E.R. Martins, A.M. Azevedo, A.C. Almeida Antioxidant activity of essential oils from condiment plants and their effect on lactic cultures and pathogenic bacteria, Ciênc Rural 49(2) (2019).
56. G. Sacchetti, S. Maietti, M. Muzzoli, M. Scaglianti, S. Manfredini, M. Radice, R. Bruni Comparative evaluation of 11 essential oils of different origin as functional antioxidants, antiradicals and antimicrobials in foods Food Chem 91(4) (2005) 621-632.
57. S. Jamuna, S. Sadullah, R. Ashokkumar, G. Shanmuganathan, S.S. Mozhi Potential antioxidant and cytoprotective effects of essential oil extracted from *Cymbopogon citratus* on OxLDL and H₂O₂ LDL induced Human Peripheral Blood Mononuclear Cells (PBMC), Food Science and Human Wellness 6(2) (2017) 60-9.
58. A.R. Khosravi, A. Sharifzadeh, D. Nikaein, Z. Almaie, H.G. Nasrabadi Chemical composition, antioxidant activity and antifungal effects of five Iranian essential oils against Candida strains isolated from urine samples. J Mycol Med., 28(2) (2018), pp. 355-360.
59. B. Bayala, I.H. Bassole, S. Maqdasy, S. Baron, J. Simpure, J.M.A. Lobaccaro *Cymbopogon citratus* and *Cymbopogon giganteus* essential oils have cytotoxic effects on tumor cell cultures. Identification of citral as a new putative anti-proliferative molecule, Biochimie 153 (2018) 162-170.

60. B. Balakrishnan, S. Paramasivam, A. Arulkumar Evaluation of the lemongrass plant (*Cymbopogon citratus*) extracted in different solvents for antioxidant and antibacterial activity against human pathogens, *Asian Pac J Trop Dis* 4(1) (2014) S134-S139.
61. M.O. Soares, R.C. Alves, P.C. Pires, M.B.P. Oliveira, A.F. Vinha Angolan *Cymbopogon citratus* used for therapeutic benefits: Nutritional composition and influence of solvents in phytochemicals content and antioxidant activity of leaf extracts, *Food Chem Toxicol* 60 (2013) 413-418.
62. C. Unuigbo, J. Enahoro, O. Erharuyi, H.A. Okeri Phytochemical analysis and antioxidant evaluation of lemon grass (*Cymbopogon citratus* DC.) Stapf leaves, *Journal of Applied Sciences and Environmental Management* 23(2) (2019) 223-228.
63. V. Francisco, G. Costa, A. Figueirinha, C. Marques, P. Pereira, B.M. Neves, M.T. Batista Anti-inflammatory activity of *Cymbopogon citratus* leaves infusion via proteasome and nuclear factor- κ B pathway inhibition: Contribution of chlorogenic acid, *J Ethnopharmacol* 148(1) (2013) 126-134.
64. V. Francisco, A. Figueirinha, G. Costa, J. Liberal, M.C. Lopes, C. García-Rodríguez, M.T. Batista Chemical characterization and anti-inflammatory activity of luteolin glycosides isolated from lemongrass, *J Funct Foods* 10 (2014) 436-443.
65. M.N. Boukhatem, M.A. Ferhat, A. Kameli, F. Saidi, H.T. Kebir Lemon grass (*Cymbopogon citratus*) essential oil as a potent anti-inflammatory and antifungal drugs, *Libyan J Med* 9(1) (2014) 25431.
66. G. Costa, J.P. Ferreira, C. Vitorino, M.E. Pina, J.J. Sousa, I.V. Figueiredo, M.T. Batista Polyphenols from *Cymbopogon citratus* leaves as topical anti-inflammatory agents, *J Ethnopharmacol* 178 (2016) 222-228.